Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573501 | 0.82 | KDM4E (0.31) | MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL23573405 | 0.76 | RAB9A (0.47) | RAB9AGAAMEN1NPC1KMT2A | |
| SCHEMBL23608632 | 0.71 | RAB9A (0.42) | RAB9AGAAMEN1NPC1KMT2A | |
| SCHEMBL23573295 | 0.69 | RAB9A (0.42) | RAB9AGAAMEN1NPC1KMT2A | |
| SCHEMBL23573415 | 0.69 | RAB9A (0.45) | RAB9AGAAMEN1NPC1KMT2A | |
| SCHEMBL9763242 | 0.69 | HTT (0.55) | RAB9AGAAMEN1NPC1KMT2A | |
| SCHEMBL23573317 | 0.69 | RAB9A (0.44) | RAB9AGAAMEN1NPC1KMT2A | |
| SCHEMBL23490029 | 0.69 | RAB9A (0.44) | RAB9AGAAMEN1NPC1KMT2A | |
| SCHEMBL23573178 | 0.69 | POLB (0.57) | POLB | |
| SCHEMBL23573402 | 0.69 | POLB (0.57) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | RAB9A 2930/4885GAA 546/4885MEN1 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.